Zoetis Inc. (NYSE:ZTS) Shares Acquired by Stock Yards Bank & Trust Co.

Stock Yards Bank & Trust Co. boosted its stake in Zoetis Inc. (NYSE:ZTS) by 26.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,712 shares of the company’s stock after buying an additional 20,681 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Zoetis were worth $17,286,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ZTS. Webster Bank N. A. increased its holdings in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the period. Neo Ivy Capital Management bought a new stake in shares of Zoetis during the fourth quarter valued at approximately $40,000. LRI Investments LLC acquired a new position in shares of Zoetis during the first quarter worth approximately $43,000. Hazlett Burt & Watson Inc. grew its holdings in Zoetis by 60.7% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after buying an additional 102 shares in the last quarter. Finally, Central Valley Advisors LLC acquired a new stake in Zoetis in the 2nd quarter valued at approximately $49,000. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZTS. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler boosted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a report on Tuesday, August 27th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $217.11.

Zoetis Stock Up 1.7 %

NYSE ZTS opened at $194.25 on Tuesday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a market capitalization of $88.00 billion, a P/E ratio of 37.43, a PEG ratio of 2.92 and a beta of 0.88. The company’s 50 day simple moving average is $183.22 and its 200 day simple moving average is $174.12. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same quarter in the previous year, the business posted $1.41 earnings per share. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. Equities research analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.